Multiplex real-time PCR for RRM1, XRCC1, TUBB3 and TS mRNA for prediction of response of non-small cell lung cancer to chemoradiotherapy

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 10, 2014, Pages 4153-4158

  Wu, Guo Qiu ^a   Liu, Nan Nan ^b   Xue, Xiu Lei ^b   Cai, Li Ting ^c   Zhang, Chen ^b   Qu, Qing Rong ^b   Yan, Xue Jiao ^b  

^a AFFILIATED ZHONGDA HOSPITAL OF SOUTHEAST UNIVERSITY   (China)

^b SOUTHEAST UNIVERSITY   (China)

^c MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

Author keywords

Cancers; Chemotherapy related markers; Multiplex quantitative real time polymerase chain reaction

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DEOXYCYTIDINE; DNA BINDING PROTEIN; GEMCITABINE; RRM1 PROTEIN, HUMAN; THYMIDYLATE SYNTHASE; TUBB3 PROTEIN, HUMAN; TUBULIN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN; X-RAY REPAIR CROSS COMPLEMENTING PROTEIN 1;

ADJUVANT CHEMORADIOTHERAPY; AGED; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; FEMALE; GENETICS; HUMAN; LUNG NEOPLASMS; MALE; MIDDLE AGED; MORTALITY; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; CHEMORADIOTHERAPY, ADJUVANT; CISPLATIN; DEOXYCYTIDINE; DNA-BINDING PROTEINS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME; TUBULIN; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84903525012     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.10.4153     Document Type: Article

References (26)

1. Bepler G, Gautam A, McIntyre LM, et al (2002). Prognostic significance of molecular genetic aberrations on chromosome segment 11p15.5 in non-small-cell lung cancer. J Clin Oncol, 20, 1353-60.
2. Bepler G, Kusmartseva I, Sharma S, et al (2006). RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol, 24, 4731-7.
3. Crino L, Weder W, van Meerbeeck J, et al (2010). Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: Esmo clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol, 21, 103-15.
4. Foekens JA, Romain S, Look MP, et al (2001). Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy. Cancer Res, 61, 1421-5.
5. Fan J, Otterlei M, Wong HK, et al (2004). XRCC1 co-localizes and physically interacts with PCNA. Nucleic Acids Res, 32, 2193-201.
6. Grem JL, Hoth DF, Hamilton JM, et al (1987). Overview of current status and future direction of clinical trials with 5-fluorouracil in combination with folinic acid. Cancer Treat Rev, 71, 1249-64.
7. Goyle S, Maraveyas A (2006). Chemotherapy for colorectal cancer. Digest Sur, 22, 401-14.
8. Grem J (1988). 5-fluorouracil plus leucovorin in cancer therapy. Principles and practice of oncology update series, 2, 1-12.
9. Leng XF, Chen MW, Xian L, et al (2012). Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy. J Exp Clin Cancer Res, 23, 31-25.
10. Popat S, Matakidou A, Houlston RS (2004). Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol, 22, 529-36.
11. Perumal M, Pillai RG, Barthel H,, et al (2006). Redistribution of nucleoside transporters to the cell membrane provides a novel approach for imaging thymidylate synthase inhibition by positron emission tomography. Cancer Res, 66, 8558-64.
12. Roberts RW, Crothers DM (1991). Specificity and stringency in DNA triplex formation. Proc Natl Acad Sci U S A, 88, 9397-401.
13. Rabik CA, Dolan ME (2007). Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rep, 33, 9-23.
14. Rosell R, Danenberg KD, Alberola V, et al (2004). Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res, 10, 1318-25.
15. Seve P, Isaac S, Tredan O, et al (2005). Expression of class iii {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res, 11, 5481-86.
16. Sokol DL, Zhang X, Lu P, et al (1998). Real time detection of DNA.RNA hybridization in living cells. Proc Natl Acad Sci U S A, 95, 11538-43.
17. Stryer L (1978). Fluorescence energy transfer as a spectroscopic ruler. Annu Rev Biochem, 47, 819-46.
18. Sun DS, Hu LK, Cai Y, et al (2014). A systematic review of risk factors for brain metastases and value of prophylactic cranial irradiation in non-small cell lung cancer. Asian Pac J Cancer Prev, 15, 1233-39.
19. Takezawa K, Okamoto I, Okamoto W, et al (2011). Thymidylate synthase as a determinant of pemetrexed sensitivity in nonsmall cell lung cancer. Br J Cancer, 104, 1594-601.
20. Tyagi S, Kramer FR (1996). Molecular beacons: Probes that fluoresce upon hybridization. Nat Biotechnol, 14, 303-8.
21. Wang L, Blasic JR Jr, Holden MJ, et al (2005). Sensitivity comparison of real-time pcr probe designs on a model DNA plasmid. Anal Biochem, 344, 257-65.
22. Weaver DA, Crawford EL, Warner KA, et al (2005). ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines. Mol Cancer, 4, 18.
23. Xie H, Jiang W, Jiang J, et al (2013). Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma. Cancer, 119, 173-81.
24. Zeng YD, Zhang L, Liao H, et al (2012). Gefitinib alone or with concomitant whole brain radiotherapy for patients with brain metastasis from non-small-cell lung cancer: a retrospective study. Asian Pac J Cancer Prev, 13, 909-14.
25. Zhang Y, Yang H, Liu J, et al (2013). High expression levels of class III beta-tubulin in resected non-small cell lung cancer patients are predictive of improved patient survival after vinorelbine-based adjuvant chemotherapy. Oncol Lett, 6, 220-6.
26. Zhang GB, Chen J, Wang LR, et al (2012). RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer. Cancer Chemother Pharmaco, 169, 1277-87.